January 24, 2019
Due to an insufficient supply for usual ordering, sodium polystyrene sulfonate (SPS) for oral or rectal suspension, which is used for the treatment of high blood potassium, has been added to the drug shortage list.
Multiple companies have cited different reasons for the drug shortage. According to CMP Pharma, an increased demand has led to a shortage of raw material that is required to manufacture the product. Perrigo has temporarily discontinued their Kionex suspension and sodium polystyrene sulfonate (sorbitol-free) suspension. Finally, Hikma is not marketing sodium polystyrene sulfonate suspension.
The products affected by the current shortage include:
- SPS Suspension, CMP Pharma, 15 gram/60 mL, 120 mL contains sorbitol bottle, NDC 46287-0006-04
- SPS Suspension, CMP Pharma, 15 gram/60 mL, 473 mL contains sorbitol bottle, NDC 46287-0006-01
- SPS Suspension, CMP Pharma, 15 gram/60 mL, 60 mL contains sorbitol bottle, 10 count, NDC 46287-0006-60
- Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 120 mL bottle, NDC 00054-0379-50
- Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 500 mL bottle, NDC 00054-0379-63
- Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 60 mL bottle, 10 count, NDC 00054-0379-51
Although Perrigo cannot estimate when they will manufacture this product again, CMP Pharma has SPS Suspension on back order and the company estimates a release date of late-January 2019.
Health care professionals should be advised that other potassium binders include Veltassa (patiromer; Relypsa) and Lokelma (sodium zirconium cyclosilicate; AstraZeneca). However, Lokelma is not expected to be available for purchase until early 2019.
ASHP. Current Drug Shortage; Sodium Polystyrene Sulfonate Oral or Rectal Suspension. Published January 22, 2019. Accessed January 24, 2019.
For more Pharmacy Learning Network articles, visit the homepage